JP2009507073A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507073A5
JP2009507073A5 JP2008530093A JP2008530093A JP2009507073A5 JP 2009507073 A5 JP2009507073 A5 JP 2009507073A5 JP 2008530093 A JP2008530093 A JP 2008530093A JP 2008530093 A JP2008530093 A JP 2008530093A JP 2009507073 A5 JP2009507073 A5 JP 2009507073A5
Authority
JP
Japan
Prior art keywords
substituted
aryl
group
heterocycloalkyl
alkylheterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/033686 external-priority patent/WO2007030362A1/en
Publication of JP2009507073A publication Critical patent/JP2009507073A/ja
Publication of JP2009507073A5 publication Critical patent/JP2009507073A5/ja
Pending legal-status Critical Current

Links

JP2008530093A 2005-09-07 2006-08-28 子宮内膜症の治療のためのikk阻害剤 Pending JP2009507073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71464505P 2005-09-07 2005-09-07
EP05109450 2005-10-11
PCT/US2006/033686 WO2007030362A1 (en) 2005-09-07 2006-08-28 Ikk inhibitors for the treatment of endometriosis

Publications (2)

Publication Number Publication Date
JP2009507073A JP2009507073A (ja) 2009-02-19
JP2009507073A5 true JP2009507073A5 (https=) 2009-10-15

Family

ID=37663766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008530093A Pending JP2009507073A (ja) 2005-09-07 2006-08-28 子宮内膜症の治療のためのikk阻害剤

Country Status (10)

Country Link
US (1) US20100069387A1 (https=)
EP (2) EP1931322B1 (https=)
JP (1) JP2009507073A (https=)
KR (1) KR20080052650A (https=)
CN (1) CN101304736A (https=)
AU (1) AU2006287767B2 (https=)
CA (1) CA2621057A1 (https=)
EA (1) EA200800755A1 (https=)
IL (1) IL189659A0 (https=)
WO (1) WO2007030362A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
JP2011529504A (ja) 2008-07-28 2011-12-08 ギリアード サイエンシーズ, インコーポレイテッド シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
WO2010144378A2 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
US9046522B2 (en) * 2009-07-24 2015-06-02 Geadic Biotec, Aie Markers for endometrial cancer
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
US10729693B2 (en) 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN119769990B (zh) * 2024-12-26 2025-09-09 大连医科大学附属第二医院 子宫内膜异位症的检测系统和治疗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0578328B1 (en) 1983-11-02 1999-12-29 Applied Research Systems ARS Holding N.V. Material and methods for the production of a heterodimeric human LH with a Met42 Val55 alpha subunit
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
MXPA03006817A (es) * 2001-02-01 2003-11-13 Bristol Myers Squibb Co Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
DE60239207D1 (de) * 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CA2540775A1 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag Medical use of tbk-1 or of inhibitors thereof

Similar Documents

Publication Publication Date Title
JP2009507073A5 (https=)
AU2021282467B2 (en) AR+ breast cancer treatment methods
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
RU2439068C2 (ru) Модуляторы mglur5
JP2007519649A5 (https=)
AU2013215251A1 (en) Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AU2006287767B2 (en) IKK inhibitors for the treatment of endometriosis
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2016512558A5 (https=)
JP2012510989A5 (https=)
JP2010513448A5 (https=)
CA2526908A1 (en) Combination of histone deacetylase inhibitors with chemotherapeutic agents
CA2669128A1 (en) Treatment for multiple myeloma
AR068947A1 (es) Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos
JP2012515787A5 (https=)
JP2013532709A5 (https=)
CZ321094A3 (en) Pharmaceutical preparation for inhibiting non-functional uterus bleeding
KR20020090153A (ko) 알콜중독 또는 알콜 의존을 위한 배합 치료
JP2009501745A5 (https=)
JP2019182865A5 (https=)
JP2016027024A5 (https=)
RU2016133285A (ru) Фармацевтические комбинации
JP2015502386A5 (https=)
JP2017502989A5 (https=)
WO2013009812A1 (en) Methods of treatment